undamentalytics Newsletter
Sign in

Ibio, Inc. income statement

In fiscal 2026, Ibio, Inc. reported revenue of $100,000, down 75.0% on the year before, operating income of −$35.1m (a -35141.0% margin) and net income of −$33.0m, or −$0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue1110210022220000
Cost of revenue—————————110————
Gross profit—————————112————
Research and development35323344541010105820
General and administrative76445811111211222219121111
Operating income−10−9−7−4−7−10−14−14−16−14−31−30−29−17−19−35
Interest expense0000012222210000
Income before tax——————————————−18−33
Income tax—000000000000000
Net income−12−6−6−4−7−10−15−16−18−16−23−50−65−25−18−33
Diluted EPS−$195.00−$70.00−$0.13−$0.06−$0.09−$0.12−$82.00−$0.15−$47.00−$30.50−$6.00−$0.58−$10.62−$0.65−$0.17−$0.32
Diluted shares (average)—————————1,256m4m4m6m38m105m104m
EBITDA−9−9−7−4−7−9−13−13−16−14−31−27−29−16−18−35

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IBIO vs LSTAAIM vs IBIOCLDX vs IBIOCLNN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ibio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ibio, Inc.